```html

Chlamydia Infection: A Complete Medical Guide

Overview

Chlamydia is a common sexually transmitted infection (STI) caused by the bacterium Chlamydia trachomatis. It can affect anyone who is sexually active, but the highest rates are seen in sexually active adolescents and young adults aged 15‑24 years. In the United States, the Centers for Disease Control and Prevention (CDC) reported more than 1.8 million cases in 2022, making it the most frequently reported bacterial STI worldwide.

Chlamydia can infect the genitals, rectum, throat, and eyes (conjunctivitis). Most infections are asymptomatic, especially in women, which contributes to its spread and the risk of long‑term complications if left untreated.

Symptoms

Because many people have no symptoms, routine screening is essential. When symptoms do appear, they usually develop 1‑3 weeks after exposure.

In Women

• Abnormal vaginal discharge – might be watery or mucopurulent.
• Burning sensation during urination (dysuria).
• Pain during sexual intercourse (dyspareunia).
• Lower abdominal or pelvic pain – can mimic menstrual cramps.
• Bleeding between periods or after intercourse.
• Rectal symptoms (if infected via anal sex): pain, discharge, or bleeding.

In Men

• Painful urination (dysuria).
• Clear or cloudy discharge from the penis.
• Testicular pain or swelling (epididymitis).
• Rectal symptoms similar to those in women.

In Both Sexes (Throat Infection)

• Sore throat
• Redness or swelling in the back of the throat

In Infants (Congenital Chlamydia)

• Conjunctivitis (eye infection)
• Pneumonia
• Failure to thrive

When symptoms are mild, they can be mistaken for a urinary tract infection (UTI) or yeast infection. If you suspect exposure, testing is the only way to confirm.

Causes and Risk Factors

Chlamydia is transmitted through sexual contact with an infected person’s genital, anal, or oral secretions. It cannot be spread through casual skin‑to‑skin contact, sharing towels, or via insects.

Key Risk Factors

• Younger age – highest incidence in 15‑24‑year‑olds.
• Multiple sexual partners or a new partner without recent testing.
• Inconsistent condom use – condoms dramatically lower risk but are not 100 % protective.
• History of other STIs – prior infections indicate higher susceptibility.
• Substance use (alcohol, drugs) that impairs judgment about safe sex.
• Pregnancy – hormonal changes can alter the genital mucosa, making infection more likely.
• Men who have sex with men (MSM) – rectal chlamydia is common in this group.

Diagnosis

Because up to 70 % of infected women and 50 % of infected men have no symptoms, routine screening is recommended for sexually active individuals under 30 and for anyone with risk factors.

Testing Methods

• Nucleic Acid Amplification Tests (NAATs) – the gold standard. Samples can be urine (first‑catch) or a swab from the cervix, vagina, urethra, rectum, or throat. NAATs detect bacterial DNA with >95 % sensitivity.
• Culture – less common, used mainly for research or antibiotic‑resistance testing.
• Direct Fluorescent Antibody (DFA) test – older method, largely replaced by NAATs.

Screening Recommendations

• Women ≤25 years: annual urine or vaginal swab NAAT.
• Women >25 years with risk factors: at least every 2 years.
• All sexually active men ≤30 years: annual urine NAAT.
• Pregnant women: first prenatal visit and in the third trimester if at risk.
• MSM: annual rectal and pharyngeal NAATs, plus urine test.

Treatment Options

Chlamydia responds to a short course of antibiotics. Early treatment eliminates the bacteria, relieves symptoms, prevents transmission, and reduces the risk of complications.

First‑Line Antibiotics

• Doxycycline 100 mg orally twice daily for 7 days – most widely recommended (CDC 2021).
• Azalide (azithromycin) 1 g orally in a single dose – useful for patients who cannot take doxycycline, such as pregnant women.

Alternative Regimens

• Levofloxacin 500 mg orally daily for 7 days (reserved for doxycycline‑resistant cases).
• Erythromycin base 500 mg four times daily for 7 days (alternative in pregnancy).

Key Treatment Points

• Both the patient and all sexual partners from the previous 60 days must be treated simultaneously.
• Abstain from vaginal, anal, and oral sex for 7 days after completing antibiotics (or until symptoms resolve).
• Retesting (test of cure) is recommended 3 months after treatment for pregnant women and for anyone with reinfection risk.

Lifestyle & Supportive Care

• Increase fluid intake to help flush the urinary tract.
• Over‑the‑counter pain relievers (ibuprofen or acetaminophen) for discomfort.
• Educate partners about safe‑sex practices to avoid re‑exposure.

Living with Chlamydia Infection

While the infection itself is short‑term, managing the experience can help maintain emotional and physical health.

Practical Daily Tips

• Complete the full antibiotic course even if symptoms disappear.
• Keep a medication log to track doses.
• Use condoms or dental dams consistently, especially during the first week after treatment.
• Maintain regular follow‑up appointments with your clinician.
• If you experience persistent symptoms after treatment, contact your provider—possible reinfection or antibiotic resistance.
• Consider partner notification services offered by health departments to ensure all contacts are treated.

Emotional & Social Support

• Stigma can be a barrier; remember that STIs are common medical conditions, not moral judgments.
• Confidential counseling or support groups (e.g., Planned Parenthood, local health clinics) can provide reassurance.
• If anxiety about future fertility arises, discuss it openly with a healthcare professional.

Prevention

Prevention combines behavioral strategies with medical interventions.

• Consistent condom use – male or female condoms reduce transmission by ~50‑60 % for chlamydia.
• Regular STI screening – at least annually for sexually active people under 30, and after any new partnership.
• Limit number of concurrent partners – fewer partners = lower probability of exposure.
• Vaccination – no vaccine exists for chlamydia, but staying up to date on HPV and hepatitis B vaccines protects against other STIs.
• Pre‑exposure prophylaxis (PEP) for STIs is an emerging research area; currently, no approved regimen exists.
• Open communication with partners about STI status and testing history.

Complications

If untreated, chlamydia can cause serious, sometimes irreversible damage.

In Women

• Pelvic Inflammatory Disease (PID) – inflammation of the uterus, fallopian tubes, and ovaries; can lead to chronic pelvic pain.
• Infertility – scarring of the fallopian tubes reduces the chance of conception.
• Ectopic pregnancy – higher risk due to tubal damage; can be life‑threatening.
• Increased HIV susceptibility – genital inflammation facilitates HIV entry.

In Men

• Epididymitis – inflammation of the tube that carries sperm; can cause painful swelling and, rarely, infertility.
• Prostatitis – chronic inflammation leading to pelvic discomfort.

In Both Sexes

• Reactive arthritis (formerly Reiter’s syndrome) – joint pain, eye inflammation, and urethritis.
• Conjunctivitis – ocular infection from autoinoculation.
• Rectal complications – perforation or chronic proctitis in those with anal infection.

When to Seek Emergency Care

References

• Centers for Disease Control and Prevention. Chlamydia – CDC Sexually Transmitted Infections (STI) Statistics. Updated 2023.
• Mayo Clinic. Chlamydia: Symptoms, Causes, and Treatment. Accessed April 2026.
• World Health Organization. Fact Sheet: Chlamydia. 2022.
• Cleveland Clinic. Chlamydia – Overview. Reviewed 2024.
• American College of Obstetricians and Gynecologists (ACOG). Practice Bulletin No. 209: Chlamydia Screening and Management. 2021.
• National Institutes of Health. Chlamydia trachomatis Infection: Pathogenesis, Complications, and Management. Clinical Microbiology Reviews, 2020.

```